FibroBiologics Files Patent for Inbody Peptide Production Technology

HOUSTON, Oct. 7, 2026 /CourierPR/ -- FibroBiologics, a clinical-stage biotechnology company with 270+ patents issued and pending, has filed a U.S. patent application for a new cell-based technology designed to continuously produce peptides such as GLP-1, GIP, and GLP-2 inside the body. The company, which is subject to the Litigation Reform Act of 1995, has announced that its new approach proposes an alternative to the repeated injections of popular GLP-1 medicines used for weight loss and diabetes. These medicines generally require patients to take weekly injections or daily pills.

Instead of receiving a GLP-1 drug through repeated injections or pills, patients would be administered the engineered cells one time and then have those cells continuously produce the desired peptide inside the body. By providing consistent levels of a potentially therapeutic peptide, the technology could reduce the need for repeated injections. The patent application specifically covers GLP-1, GIP, and GLP-2 class peptides, among many other potential medicines.

The patent application describes engineering living cells to act like tiny peptide factories inside the body. These cells would be grouped together into small three-dimensional structures called spheroids or organoids. Once administered to a patient, they are designed to continuously produce and release a therapeutic peptide. The application is not limited to weight-loss or diabetes indications, it also describes possible applications in gastrointestinal diseases, autoimmune and inflammatory diseases, wound healing, tissue regeneration, hormone deficiencies, cancer, and age-related conditions.

The technology could potentially be used to produce many different therapeutic proteins and peptides. The technology could also allow different potentially therapeutic peptides to be produced at the same time and in different amounts depending on the disease or patient. A single administration is designed to supply steady, physiological levels of the desired peptide, offering a potential alternative to the weekly injections of currently available peptides.

FibroBiologics, based in Houston, is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration.

FibroBiologics gives no assurance that it will achieve its expectations. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.